Table 6.
Table showing the change in the log-likelihood of the models with added prognostic terms.
| Variables | Disease-free survival |
Overall survival |
||
|---|---|---|---|---|
| ΔLRχ2 | pValue | ΔLRχ2 | pValue | |
| CP + iCD38 PC vs. CP | 17.28 | 1.71E−08* | 10.03 | 6.32E−08* |
| CP + IGKC vs. CP | 18.45 | 9.91E−09* | 14.26 | 8.74E−09* |
| CP + IGHM vs. CP | 15.44 | 4.04E−08* | 15.14 | 5.78E−09* |
| CP + IGHG1 vs. CP | 21.99 | 1.88E−09* | 16.23 | 3.47E−09* |
| CP + IgG genes vs. CP | 7.74 | 1.43E−06* | 6.12 | 3.89E−07* |
| CP + iCD38 PC + IGHG1 vs. CP | 27.38 | 5.22E−10* | 21.29 | 1.03E−08* |
Statistical significance of the change was determined by a likelihood ratio test.
*Statistically significant; CP, clinicopathological parameters (patient age, tumor grade, tumor size, and lymph node status); iCD38 PC, intratumoral CD38+ plasma cell density; IgG genes, expression level of a panel of IgG genes (Table S7 in Supplementary Material); LR, likelihood ratio.